电穿孔与皮内递送增强四价登革DNA疫苗免疫原性及保护效力
该研究在非人灵长类中比较四价登革DNA疫苗不同剂量(1 mg或5 mg)与递送方式(皮内或肌内,无针注射或电穿孔)的免疫效果。结果显示所有新方法均优于既往高剂量无针肌内注射组,高剂量皮内电穿孔组中和抗体与IFN-γ T细胞反应最高,且接种一年多后攻毒时低、高剂量皮内电穿孔组登革-1病毒RNA血症天数显著少于对照组。
要点
- 皮内电穿孔递送高剂量DNA疫苗诱导最强中和抗体与IFN-γ T细胞反应。
- 所有新递送方式免疫应答均优于既往高剂量无针肌内注射。
- 接种一年多后攻毒,皮内电穿孔组登革-1病毒RNA血症天数显著减少。
核心结论
- 使用电穿孔装置和/或皮内途径可增强该四价登革DNA疫苗在非人灵长类中的免疫应答,值得在人体中探索。
研究设计与样本
- 非人灵长类研究,动物于第0、28、91天接种低剂量(1 mg)或高剂量(5 mg)疫苗,经皮内或肌内途径,使用无针注射或电穿孔装置。
- 对照组为经无针肌内注射装置接种高剂量的组,该装置类似既往临床前和临床研究所用。
主要发现
- 所有既往未测试的接种方法均比高剂量无针肌内注射组引发更好的免疫应答。
- 高剂量皮内电穿孔组的中和抗体应答最高,IFN-γ T细胞应答也最高,CD8+ T细胞是IFNγ应答的主要贡献者。
- 针对全部四种血清型的记忆B细胞均可检测到。
- 接种一年多后以登革-1病毒攻毒,低剂量和高剂量皮内电穿孔组的登革-1病毒RNA血症天数均显著少于对照组。
临床怎么用
- 在非人灵长类中,皮内电穿孔递送可增强四价登革DNA疫苗的免疫原性和攻毒保护,提示应进一步在人体中评估该递送方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phase 1 clinical trials with a DNA vaccine for dengue demonstrated that the vaccine is safe and well tolerated, however it produced less than optimal humoral immune responses. To determine if the immunogenicity of the tetravalent dengue DNA vaccine could be enhanced, we explored alternate, yet to be tested, methods of vaccine administration in non-human primates. Animals were vaccinated on days 0, 28 and 91 with either a low (1 mg) or high (5 mg) dose of vaccine by the intradermal or intramuscular route, using either needle-free injection or electroporation devices. Neutralizing antibody, IFN-γ T cell and memory B cell responses were compared to a high dose group vaccinated with a needle-free intramuscular injection delivery device similar to what had been used in previous preclinical and clinical studies. All previously untested vaccination methodologies elicited improved immune responses compared to the high dose needle-free intramuscular injection delivery group. The highest neutralizing antibody responses were observed in the group that was vaccinated with the high dose formulation via intradermal electroporation. The highest IFN-γ T cell responses were also observed in the high dose intradermal electroporation group and the CD8+ T cells were the dominant contributors for the IFNγ response. Memory B cells were detected for all four serotypes. More than a year after vaccination, groups were challenged with dengue-1 virus. Both the low and high dose intradermal electroporation groups had significantly fewer days of dengue-1 virus RNAemia compared to the control group. The results from this study demonstrate that using either an electroporation device and/or the intradermal route of delivery increases the immune response generated by this vaccine in non-human primates and should be explored in humans.
引用
- Williams M, Ewing D, Blevins M, et al. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery. Vaccine. 2019. PMID: 31279565. doi:10.1016/j.vaccine.2019.06.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。